REGN Stock Recent News

Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out.

REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).

Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitive customer DNA information.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosimilars entered the market, stalling overall company growth. Dupixent continues strong growth with new approvals in COPD and CSU, keeping Regeneron profitable despite challenges.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine.

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innovative global healthcare company, and Regeneron (NASDAQ: REGN), a leading biotechnology company, to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease (COPD). With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care a.

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash. The transaction, which excludes 23andMe's telehealth unit, is pending approval from a bankruptcy court, with the deal expected to close in the third quarter of 2025.

Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.